Anti-HDV Seroprevalence Among Patients with Chronic Hepatitis B Infection in Diyarbakır

Diyarbakır’da Kronik Hepatit B Enfeksiyonu Olan Hastalarda Anti-HDV Seroprevalansı

© Muhammed Bekçibaşı1, © Eyüp Arslan2

1University of Health Sciences Turkey, Gazi Yaşargil Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Diyarbakır, Turkey
2Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, İstanbul, Turkey

ABSTRACT

Objectives: This study identifies the hepatitis delta virus (HDV) antibodies (anti-HDV) seroprevalence in patients with chronic hepatitis B (CHB) infection in a region highly endemic for HDV.

Materials and Methods: A total of 306 patients with CHB infection, who were followed up regularly between January 2016 and December 2019, were retrospectively analyzed. Demographic characteristics, hematological parameters, liver function tests, abdominal ultrasonography, hepatitis serologies, and liver biopsy results of the patients were analyzed through patient follow-up forms.

Results: Anti-HDV was positive in 43 (14.1%) of 306 patients, 129 (42.1%) of whom were female and had a mean age of 41.5±13.4 years. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamil transferase levels of delta hepatitis (DH) patients were significantly higher than those of CHB patients (p=0.019, p<0.001; p=0.027; p=0.001, respectively), whereas albumin, white blood cell, and platelet levels were significantly lower (p<0.001; p=0.001; p<0.001, respectively). 55.8% of patients with DH were diagnosed with cirrhosis.

Conclusion: Anti-HDV was positive in 14.1% of patients diagnosed with CHB in the Diyarbakır region. The progression to liver cirrhosis and hepatocellular carcinoma is faster in DH; therefore, more efforts should be made to identify and treat this patient group.

Keywords: Anti-HDV, hepatitis B virus, hepatitis delta virus, seroprevalence

Cite this article as: Bekçibaşı M, Arslan E. Anti-HDV Seroprevalence Among Patients with Chronic Hepatitis B Infection in Diyarbakır.
Viral Hepatitis Journal 2022;28(2):89-93
Introduction

Hepatitis delta virus (HDV) is a small, defective RNA virus with a viroid structure. HDV can only spread to an individual with hepatitis B virus (HBV) by simultaneous transmission of two viruses (coinfection) or by the infection of an HBV carrier with HDV (superinfection) (1). Spontaneous recovery occurs in 95% of the patients with HBV/HDV coinfection. However, it may cause extensive hepatic necrosis in the remaining patients and lead to a presentation of fulminant hepatitis with high mortality rates (2). Superinfection of people with chronic hepatitis B (CHB) infection with HDV results in turning into chronic at a rate of 80%, which leads to accelerated progression to cirrhosis and an increased risk of hepatocellular carcinoma (HCC) compared to CHB infection alone (3). It is estimated that 0.16% of the general population, which approximately equals 12 million people, are anti-HDV positive worldwide. The prevalence of anti-HDV was reported to be 4.5% among all HBsAg-positive individuals and 16.4% among those presenting to hepatology clinics (4). In Turkey, the lowest prevalence of delta hepatitis (DH) in CHB patients is observed in the West with 4.8%, while the highest prevalence is observed in the Southeast with a rate of 27.1%. In recent years, there has been a decrease in DH in Turkey after the national HBV vaccination program; however, the prevalence is still high in the Southeastern and Eastern Anatolia Regions and continues to be an important health problem (5). The study aims to identify the anti-HDV seroprevalence in CHB patients in a region highly endemic for HDV.

Materials and Methods

Study Design

This study was approved by the Clinical Research Ethics Committee of University of Health Sciences Turkey, Gazi Yaşargil Training and Research Hospital (approval number: 725, date: 26.03.2021).

This study is a retrospective analysis of medical data obtained from the Infectious Diseases Outpatient Clinic of Diyarbakır Bismil State Hospital. A total of 306 patients diagnosed with CHB infection, who were followed up regularly between January 2016 and December 2019, were included in the study. Demographic characteristics, hematological parameters, liver function tests, abdominal ultrasonography, hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), anti-HBe, anti-HDV immunoglobulin G, HBV-DNA, HDV-RNA, and liver biopsy results of the patients were analyzed through patient follow-up forms. Serological tests were performed using the macro-ELISA method (Architect i2000SR, Abbott Diagnostics, Chicago, IL, USA). Anti-HDV presence was analyzed using the Triturus (Triturus, Grifols, Spain) and the micro-ELISA (HDV Ab, Enzyme Immunoassay Test Kit, Delta Biologicals, Italy) systems according to the manufacturer’s instructions. The presence of HBV-DNA and HDV-RNA was evaluated by real-time polymerase chain reaction (PCR) using the Rotor-Gene Q (QIAGEN, Germany) system and the HBV QS-RG PCR kit (Qiagen, Hilden, Germany) with a linear range of detection of 25.6-4.21x10^8 IU/mL.

Definitions

CHB infection was defined as the patient group known to be HBsAg positive for more than six months with serological and molecular test confirmation.

The diagnosis of liver cirrhosis was defined in patients who met at least one of the following items:

1. Hepatic surface irregularity, caudate lobe hypertrophy, splenomegaly, or hepatic parenchymal damage on ultrasonography.
2. Laboratory and histological analysis results,
3. Esophageal varices confirmed by endoscopy.

Patients with co-infection with hepatitis C virus and human immunodeficiency virus, or chronic liver diseases such as primary biliary cirrhosis, autoimmune hepatitis, and alcoholic hepatitis, and patients under the age of 16 were excluded from the study. Patients with acute hepatitis B, defined by the presence of HBsAg for less than six months and a clinical presentation compatible with recent HBV infection, were excluded from the study.

Statistical Analysis

Continuous variables were compared using the Independent samples t-test. Categorical variables were compared using the Pearson chi-square or the Fisher’s exact test. All tests were performed using the SPSS for Windows version 18.0 software (SPSS Inc. Chicago, IL, USA). A p-value of <0.05 was considered statistically significant.

Results

A total of 129 (42.1%) of the 306 patients included in the study were female and the mean age was 41.5±13.4 years. HBeAg was positive in 9.1% of the patients. 28.4% of the patients had undetectable HBV-DNA and 20.9% of HBsAg (+) patients were receiving oral antiviral therapy for HBV. HDV antibodies (anti-HDV+) were positive in 43 (14.1%) of the patients. HDV-RNA was above the detectable level in 17 (39.5%) of the anti-HDV (+) patients. Pegile interferon alfa 2 treatment was given to 19 (44.1%) of the anti-HDV positive patients for 48 months, and 4 (9.3%) for a total of 96 months. Liver transplantation was performed in 2 (4.6%) anti-HDV positive patients. The mean age of the anti-HDV (+) patients was significantly higher than that of the anti-HDV (-) patients (p<0.001). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) levels in anti-HDV (+) patients were significantly higher than those of anti-HDV (-) patients based on the analysis of the biochemical data (p=0.019; p<0.001; p=0.027; p=0.001, respectively). The anti-HDV (+) patients had significantly lower albumin, white blood cell count (WBC), and platelet levels compared to the anti-HDV (-) patients (p<0.001; p=0.001; p<0.001, respectively). While more than half of the anti-HDV (+) patients were diagnosed with liver cirrhosis, this rate was very low in the anti-HDV (-) patient group (55.8% vs 1.9%, p<0.001). The distribution of demographic, biochemical, and hematological characteristics of the study participants according to the groups is shown in Table 1.
Discussion

It is estimated that more than 15 million of the 350 million CHB carriers worldwide are exposed to HDV (6). Similar to HBV, HDV is transmitted parenterally through exposure to infected blood or body fluids. Therefore, transmission rates are high in intravenous drug users (7). There is evidence of sexual transmission, and people with high-risk sexual activity are at greater risk for infection (8). Intrafamilial transmission, known as non-specific parenteral transmission, is common in areas with high HDV prevalence. On the other hand, perinatal transmission of HDV is rare. Despite the antiviral therapies used in HDV treatment, these patients are subject to increased liver decompensation, which leads to faster progression to cirrhosis and death, compared to those with HBV infection alone (9). In a viral hepatitis prevalence study in which a large population was screened in Turkey, a middle-endemic country for HBV, anti-HDV positivity was found in 2.8% of the patients with HBsAg positivity (10). The eastern and southeastern parts of Turkey are especially the regions with the highest prevalence of DH. The prevalence of DH in the east and southeast of the country has been associated with the low socioeconomic status of these regions which represent the poorest regions of Turkey (5).

In the present study, anti-HDV positivity was identified in 14.1% of HBsAg (+) patients. More than half of the DH patients (55.8%) were diagnosed with cirrhosis. In a meta-analysis study in which studies conducted in Turkey between 1995 and 2004 were evaluated, anti-HDV seropositivity in patients diagnosed with CHB was reported to be the lowest in the western region with a rate of 5% and the highest in the southeast region with a rate of 27%. In the same study, anti-HDV seropositivities in patients with cirrhosis caused by hepatitis B were at a rate of 20% in the western region and 46% in the southeast region (5). In studies conducted after 2010, anti-HDV positivity in HBsAg (+) patients has been reported to be the lowest in the Western regions, within a range of 1.4-4.1% (11,12,13,14). The rate was within the range of 0.9-4.2% in studies conducted in the middle Anatolia regions (15,16,17). As in previous years, the highest rates have been observed in the East (8.8-15.2%) and Southeast (3.2-27.8%) regions in studies conducted after 2010 (18,19,20,21,22,23,24). Recent studies in Turkey are summarized in Table 2.

In the present study, ALT, AST, ALP, and GGT levels of the DH patients were significantly higher than those of the CHB patients (p=0.019; p<0.001; p=0.027; p=0.001, respectively), while albumin, WBC, and platelet levels were significantly lower (p<0.001; p=0.001; p<0.001, respectively). The presence of cirrhosis in 55.8% of the DH patients suggests the laboratory changes that occurred. Studies have shown that DH patients have significantly higher ALT levels and histological activity compared to CHB patients who are not infected with HDV (25). In a recent meta-analysis, it was shown that DH progresses to cirrhosis within a mean of five years and HCC within a mean of 10 years (26).

Study Limitations

There are some limitations to the present study. It was single-centered, retrospective, and had a relatively small sample size. Moreover, sequential HDV-RNA monitoring could not be performed in some of the patients.

Conclusion

In the present study, the anti-HDV seroprevalence of the patients with CHB infection was identified above the Turkey average and close to the average of the data reported from the Eastern and Southeastern regions with a rate of 14.1%. Agents

Table 1. Clinical, demographic features, and laboratory data of the participants

|                        | Anti-HDV positive | Anti-HDV negative | p-value |
|------------------------|-------------------|-------------------|---------|
| Patient count, n (%)   | 43 (14.1)         | 263 (85.9)        |         |
| Age, years, mean ± SD  | 51.7±11.3         | 39.9±12.9         | <0.001  |
| Sex, female n (%)      | 17 (39.5)         | 112 (42.6)        | 0.834   |
| ALT (U/L)              | 50.7±32.2         | 37.0±35.9         | 0.019   |
| AST (U/L)              | 50.2±28.4         | 29.0±16.1         | <0.001  |
| ALP (U/L)              | 105.8±47.8        | 87.2±45.4         | 0.027   |
| GGT (U/L)              | 68.4±69.2         | 24.2±18.9         | 0.001   |
| Albumin (g/dL)         | 3.86±0.059        | 4.39±0.40         | <0.001  |
| Total bilirubin (mg/dL)| 0.80±0.57         | 0.67±0.47         | 0.091   |
| Creatinine (mg/dL)     | 0.82±0.14         | 0.86±0.16         | 0.154   |
| White blood count (mm³)| 6375±1841         | 7450±2019         | 0.001   |
| Hemoglobin (g/dL)      | 14.6±1.8          | 14.8±1.8          | 0.620   |
| Platelet (mm³)         | 150198±56492      | 211630±59039      | <0.001  |
| INR                    | 1.14±0.13         | 1.08±0.69         | 0.609   |
| AFP                    | 8.21±21.15        | 7.18±20.13        | 0.778   |
| Liver cirrhosis n (%)  | 24 (55.8)         | 5 (1.9)           | <0.001  |
| CTP score              | 5.3±0.9           | 5.1±0.3           | 0.054   |

HDV: Hepatitis delta virus, SD: Standard deviation, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, ALP: Alkaline phosphatase, GGT: Gamma-glutamyl transferase, INR: International normalized ratio, AFP: Alpha-fetoprotein, CTP: Child-Turcotte-Pugh
that can be used in the treatment of DH are limited, and response rates are very low; therefore, more efforts should be made to minimize the proportion of undiagnosed or not regularly followed-up CHB patients. In addition, HBV vaccination should be applied effectively not only in childhood but also in all risk groups in endemic regions.

**Ethics**

**Ethics Committee Approval:** This study was approved by the Clinical Research Ethics Committee of University of Health Sciences Turkey, Gazi Yaşargil Training and Research Hospital (approval number: 725, date: 26.03.2021).

**Informed Consent:** Retrospective study.

**Peer-review:** Externally peer-reviewed.

**Authorship Contributions**

Surgical and Medical Practices: M.B., E.A., Concept: M.B., E.A., Design: M.B., Data Collection or Processing: M.B., E.A., Analysis or Interpretation: M.B., Literature Search: M.B., Writing: M.B.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declare no financial support.

**References**

1. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73-85.
2. Botelho-Souza LF, Vasconcelos MPA, Dos Santos AQ, Salcedo JMV, Vieira DS. Hepatitis delta: virological and clinical aspects. Virol J. 2017;14:177.
3. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int. 2011;31:7-21.
4. Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73:523-532.
5. Değerterkin H, Yalçınt K, Yakut M, Yurdaydın C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;28:494-498.
6. Farci P. Delta hepatitis: An update. J Hepatol. 2003;39(Suppl1):S212-S219.
7. Wu JC, Chen CM, Sheen IJ, Lee SD, Tzeng HM, Choo KB. Evidence of transmission of hepatitis D virus to spouses from sequence analysis of the viral genome. Hepatology. 1995;22:1656-1660.
8. Rosenblum L, Darrow W, Witte J, Cohen J, French J, Gill PS, Potterat J, Sikes K, Reich R, Hadler S. Sexual practices in the transmission of hepatitis B virus and prevalence of hepatitis delta virus infection in female prostitutes in the United States. JAMA. 1992;267:2477-2481.
9. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629-1638.
10. Tozun N, Ozdoğan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoğlu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-1026.
11. Ergen P, Yılmaz Karadağ F, Aydın Ö. Investigating the Prevalence of Hepatitis Delta and Assessment of Treatment Response. Viral Hepat J. 2020;26:135-140.
12. Aydemir Ö, Terzi HA, Karakaş E, Köroğlu M, Altimiş M. Delta hepatitis positivity in hepatitis B virus infected patients; confection or superinfection? FLORA. 2019;24:131-135.
13. Kaya S, Karabey M, Güngör S, Baran N, Şener A, Aftar İ. Evaluation of Hepatitis D Virus serology results of İzmir Katip Celebi University Ataizik Training and Research Hospital. J Immunol Clin Microbiol. 2019;4:91-96.
14. Yolcu A, Karabulut N, Alacan M, Önel M, Büyük M, Gülüşoğlu M, Ağacıfıadan A. Frequency of hepatitis delta virus in hepatitis b surface antigen-positive patients. Viral Hepat J. 2019;25:14-18.

**Table 2. Anti-HDV positivity in patients with chronic hepatitis B in Turkey**

| Region       | Study period | Researcher          | Anti-HDV (+) |
|--------------|--------------|---------------------|--------------|
| West Turkey  |              |                     |              |
| İstanbul     | 2015-2017    | Yolcu et al. (14)   | 4.1%         |
| İstanbul     | 2015-2019    | Ergen et al. (11)   | 2.9%         |
| İzmir        | 2016-2018    | Kaya et al. (13)    | 2.8%         |
| Sakarya      | 2015-2018    | Aydemir et al. (12) | 1.4%         |
| Central Turkey|              |                     |              |
| Ankara       | 2010-2013    | Gürkan et al. (15)  | 4.2%         |
| Ankara       | 2012-2014    | Yozgat et al. (17)  | 3.0%         |
| Eskişehir    | 2012-2013    | Korkmaz et al. (16) | 0.9%         |
| East Turkey  |              |                     |              |
| Elazığ       | 2017-2019    | Eser-Karlıdağ (20)  | 8.8%         |
| Malatya      | 2012         | Duman et al. (19)   | 15%          |
| Van          | 2012-2014    | Dulger et al. (18)  | 15.2%        |
| Southeast Turkey|           |                     |              |
| Adıyaman     | 2010-2012    | Kölçeli et al. (23) | 3.2%         |
| Diyarbakır   | 2012-2017    | Ayaz and Sari (21)  | 4.4%         |
| Siirt        | 2017-2018    | Bal (22)            | 27.8%        |
| Şanlıurfa    | 2011-2012    | Uyanıkolu et al. (24) | 5.0%     |

HDV: Hepatitis delta virus
15. Gürkan Y, Toyran A, Aksoy A, Coşkun FA, Çetin F: Evaluation of HBsAg and Anti-HDV Seroprevalence of Patients who Admitted to Ankara Numune Training and Research Hospital Between 2010 - 2013. Viral Hepat J. 2013;19:148-151.

16. Korkmaz P, Aykın N, Çağlan Çevik F, Güldüren HM, Alpay Y: Seropositivity of delta hepatitis in HBsAg positive patients in Eskişehir province. Viral Hepat J. 2014;20:72-74.

17. Yozgat A, Alısparmak E, Demirci S, Çağlayan Ö, Alıyazıcıoğlu M, Kızıleoğlu H, Erten AT, Çetin F, Uner E, Özşahan E, Altınbaş A: Delta hepatitis frequency in chronic hepatitis B Patients: Single center retrospective study. Ortadoğu Medical Journal. 2015;7:12-15.

18. Dulger AC, Suvak B, Gorullu H, Gorullu E, Gultepe B, Aydın İ, Batur A, Karadas S, Olmez Ş: High prevalence of chronic hepatitis D virus infection in Eastern Turkey: Urbanization of the disease. Arch Medical Science. 2016;12:415-20.

19. Duman Y, Tekerekoglu MS, Ay S: Seroprevalence of HBsAg, Anti-HBs, anti-HDV and HDVAg in İnönü University Medical Faculty Hospital, 2012. Medicine Science. 2014;3:982-990.

20. Eser-Karlıdağ G: Prevalence of hepatitis delta in chronic hepatitis B patients. Klinik Derg. 2019;32:281-284 (Turkish).

21. Ayaz C, San T: Treatment results of chronic delta hepatitis patients. Ortadoğu Tip Derg. 2019;11:73-77 (Turkish).

22. Bal T: High prevalence of hepatitis delta antibody in Siirt Province. J DU Sci Inst. 2021;11:45-49 (Turkish).

23. Kölgelier S, Aktuğ Demir N, Özçimen S: Seropositivity of delta hepatitis in HBsAg positive patients in Adıyaman Province. Viral Hepat J. 2013;19:8-10.

24. Uyanıkoğlu A, Sert U, Çetin B, Uyanıkoğlu H, Yenice N: The distribution clinical and demographic features of HBsAg positive patients in Şanlıurfa Region. Viral Hepat J. 2015;21:89-93.

25. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M: Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat. 2011;18:518-524.

26. Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, Peppelenbosch MP, Liu J, Pan Q: Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020;221:1677-1687.